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Abstract
Background: Venous thromboembolism is a common postoperative complication following orthopedic surgeries,
with morbid and potentially fatal consequences. Perioperative low-molecular-weight heparin (LMWH) therapy can
reduce the incidence of venous thromboembolism, but may also increase the risk of bleeding complications.
Current literature reflects the need to balance the improved efficacy of early initiating prophylaxis with increased
risk of perioperative bleeding. The purpose of this study was to compare the effectiveness and hemorrhage related
safety of preoperative versus postoperative LMWH therapy for prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE) in hip fracture patients.
Methods: We retrospectively evaluated 222 patients who underwent surgical treatment at Peking University
People's Hospital between January 2009 and December 2010. Patients were allocated to two groups, receiving
either preoperative or postoperative initiation of LMWH therapy for venous thromboembolism prophylaxis.
Preoperative anticoagulation therapy was initiated 1–12 days prior to surgery (133 patients), and postoperative
anticoagulation therapy was initiated 12 h after completion of surgery (89 patients). The preoperative group was
further subdivided into four subgroups according to the time of initiation of therapy: 1–3 days before surgery
(group A, 54 patients), 4–6 days before surgery (group B, 57 patients), 7–9 days before surgery (group C, 15
patients), and 10–12 days before surgery (group D, 7 patients). Occurrences of DVT, PE, adverse drug effects,
intraoperative and postoperative bleeding were recorded, along with concentrations of preoperative and
postoperative hemoglobin and length of hospital stay. The above parameters were compared between groups.
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Results: Among recipients of preoperative anticoagulation therapy, two patients developed postoperative PE
(1.5 %), one patient developed DVT (0.75 %). In the group receiving postoperative initiation of anticoagulation
therapy, one patient each developed PE and DVT (1.1 %, 1.1 %). There was no difference in the occurrence of PE
and DVT between the two groups (P>0.05, Chi-square tests). We identified the incidences of major bleeding, minor
bleeding, and intraspinal hematoma after spinal anesthesia, which were 0 %/0 %, 3.76 %/3.37 %, and 0 %/0 %,
respectively in preoperative and postoperative anticoagulation groups. There was no significant difference in the
incidence of bleeding complications between patients receiving preoperatively initiated LMWH with patients
receiving postoperatively initiated LMWH. Spinal anesthesia was administered to 168 patients, with no cases of
postoperative intraspinal hematoma.
Conclusions: Preoperative anticoagulation therapy with LMWH may not increase intraoperative or postoperative
blood loss, or the rate of intraspinal hematoma after spinal anesthesia, but also does not significantly reduce the
risk of postoperative DVT or PE, compared to postoperative initiation.
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Background
Surgical intervention is the most common form of treat-
ment for hip fractures. Surgeries like total hip arthro-
plasty and hip fracture fixation often lead to
postoperative venous thromboembolism (VTE), associ-
ated with high mortality rates [1, 2]. For patients under-
going surgery for hip fracture, the latest guidelines for
prevention of deep venous thrombosis (DVT) by the
American College of Chest Physicians (ACCP) (2012,
9th edition) recommend initiation of routine subcutane-
ous low-molecular-weight heparin (LMWH) therapy ei-
ther from at least 12 h before surgery, or at least 12 h
after surgery (two to four hours after removal of the epi-
dural catheter) [2, 3]. Perioperative LMWH therapy, al-
though useful for preventing VTE, may increase the risk
of intraoperative and postoperative bleeding [4]. The
guidelines do not provide any comparisons of effective-
ness and safety between preoperative and postoperative
initiation of LMWH therapy. Hull et al. [5] performed a
literature review and found that the timing of initiation
of LMWH therapy significantly affected the effectiveness
of DVT prophylaxis. In another review, Perka [6] re-
ported no difference in the effectiveness of preoperative
versus postoperative initiation of anticoagulation therapy
for DVT prophylaxis. It is important to take into consid-
eration both effectiveness and safety of the regimes when
determining the optimal time for initiation of anticoagu-
lation therapy in patients undergoing orthopedic surger-
ies for which DVT prophylaxis is indicated [7, 8].
Preoperative initiation of anticoagulation therapy can ef-
fectively reduce the risk of DVT, but, on the other hand,
may increase the risk of intraoperative and postoperative
bleeding [9, 10]. Further, among patients receiving spinal
anesthesia, preoperative initiation of anticoagulation
therapy may increase the risk of intraspinal hematoma.
Postoperative initiation of anticoagulation therapy
reduces the likelihood of bleeding complications, but
may not be as effective as preoperative regimen in pre-
venting DVT. Thus, it is not surprising that consensus
on optimal time for initiation of anticoagulation therapy
is yet to be reached [11, 12]. Regardless of the drug used,
benefits (prevention of VTE) and risks (bleeding and
intraspinal hematoma) should be taken into account
while deciding whether to administer anticoagulation
therapy [13]. Such decision making depends on many
parameters such as type of drug, drug dosage, timing of
drug administration, surgical procedure, medical history,
condition of the patient etc. In clinical practice, the tim-
ing of initiation of anticoagulation therapy varies widely
across geographical region [5, 14]. This retrospective
study analyzed outcomes of perioperative anticoagula-
tion therapy in 222 patients who underwent surgery for
treatment of femoral neck or intertrochanteric fractures,
between January 2009 and December 2010 at Peking
University People’s hospital, to evaluate the effectiveness
and safety of pre- and postoperative initiation of anticoa-
gulation therapy for DVT prophylaxis. As the optimal
regimen is uncertain because direct comparisons among
different regimens with sufficient large sample sizes are
not available, our study may provide a reference in




This study enrolled hip fracture patients who underwent
surgical treatment between January 2009 and December
2010 in the Department of Orthopedics and Trauma at
Peking University People's Hospital. Study subject selec-
tion criteria were determined so as to avoid the influ-
ence of known risk factors on outcomes [15, 16]. The
inclusion criteria were: (1) surgical treatment for hip
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fracture, especially total hip arthroplasty; (2) age >40
years; (3) weight 40–100 kg; (4) no preoperative signs/
symptoms of DVT such as lower limb swelling, pain,
stiffness, superficial venous congestion, or increased skin
temperature; (5) no preoperative signs/symptoms of pul-
monary embolism (PE) such as dyspnea, chest pain, or
cough; and, (6) VTE prophylaxis with LMWH. Patients
with multiple fractures, hemorrhagic diseases or other
contraindications to anticoagulation therapy (e.g., those
taking oral anticoagulants, or platelet inhibitors, experi-
encing any active bleeding; having history of heparin-
induced thrombocytopenia, platelet count <100,000/
mm3etc.) were excluded. As per the ACCP guidelines,
all included patients were in the high-risk group for
VTE [1]. Occurrences of deep venous thrombosis, pul-
monary embolism, adverse drug effects, intraoperative
and postoperative bleeding were recorded, along with
concentrations of preoperative and postoperative
hemoglobin, blood loss, post-surgical wound drainage,
duration of surgery and length of hospital stay. The
above parameters were compared between groups.
Ethics statement
Written informed consent was obtained from all partici-
pants, and the study was approved by the Ethics Com-
mittee of People's Hospital, Peking University. All
clinical investigations are conducted according to the
principles expressed in the Declaration of Helsinki.
Prevention of VTE
Study subjects were categorized into two groups accord-
ing to time of initiation of LMWH therapy — 1) pre-
operative and 2) postoperative. Patients in both groups
received subcutaneous LMWH (Fraxiparine; GlaxoS-
mithKline, Notre Dame de Bondeville, France), 4100
units daily until discharge. The timing of initiation of
therapy was based on respective physician’s preference,
and not on the preoperative condition of the patient.
Preoperative anticoagulation therapy was initiated 1–12
days prior to surgery, and postoperative anticoagulation
therapy was initiated 12 h after completion of surgery.
The preoperative group was further subdivided into four
subgroups according to the time of initiation of therapy:
1–3 days before surgery (group A), 4–6 days before sur-
gery (group B), 7–9 days before surgery (group C), and
10–12 days before surgery (group D). All study patients
were subjected to basic preventive measures, including
care to avoid of intraoperative injury to the intima, regu-
lar postoperative turning, early functional exercises, and
elastic stockings. Drains were removed when the drain-
age volume got reduced to <50 mL/24 h. The mean
duration of hospitalization was 20±5 days in patients
who received preoperative anticoagulation therapy and
19 ± 6 days in patients receiving only postoperative
anticoagulation therapy. Patients were encouraged to
walk following discharge in order to reduce the risk of
DVT.
Method of anesthesia
The American Academy of Orthopedic Surgeons (AAOS)
guidelines recommend spinal, epidural, or combined
spinal-epidural anesthesia for patients undergoing total
hip or total knee arthroplasty [17]. Preoperative anti-
thrombotic and antiplatelet therapy is often administered
to orthopedic patients to prevent postoperative DVT [18].
Although such prophylactic measures have been reported
to increase the risk of intraspinal hematoma, it has also
been shown that with appropriate dosage and timing,
anticoagulation therapy can prove to be safe and effective
in patients undergoing spinal anesthesia [19]. In our study,
168 patients received spinal anesthesia; while 54 patients
did not – owing to structural deformity of vertebral col-
umn or previous thoracolumbar trauma. Preoperative
anticoagulation therapy was not considered as a contra-
indication to spinal anesthesia.
Effectiveness of LMWH therapy
Patients in both groups underwent routine preoperative
and postoperative blood tests including liver and kidney
function tests, and urine tests. Specific investigations for
DVT were conducted if any of the patients developed
sudden onset of lower limb swelling, pain, numbness,
superficial venous congestion, or increase in skin
temperature. Investigations for PE were undertaken if
anyone developed dyspnea, chest pain, hemoptysis, or
cyanosis. D-dimer levels were also assessed for patients
with suspected VTE. Lower limb compression color
Doppler ultrasonography and computed tomography
pulmonary angiography were performed as needed. Posi-
tive imaging findings were mandatory requirements for
definitive diagnosis of DVT.
Safety of LMWH therapy
Medical records of study patients including postoperative
wound drainage, drain removal time, volumes of wound
bleeding, hematoma formation, and changes in lower limb
sensation or muscle strength were reviewed. Preoperative
(the day before surgery) and postoperative (the day after
surgery) laboratory test results were compared to detect
presence of major bleeding, thrombocytopenia, and any sig-
nificant changes in organ function. Major bleeding was de-
fined as any of the following: decrease in hemoglobin
concentration by 20 g/L or more within 24 h, need for
transfusion of more than 2 units of red blood cells based
on change in hemoglobin concentration, evidence of major
organ bleeding such as intracranial or gastrointestinal
bleeding, intraoperative bleeding needing surgical interven-
tion, or intramuscular bleeding resulting in compartment
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syndrome [20]. All other types of bleeding were classified
as minor. Thrombocytopenia was defined as either a reduc-
tion in platelet concentration from >150 × 1019/L (pre-
operative) to <100 × 1019/L (postoperative), or a >50 %
decrease during postoperative period from a preoperative
concentration of <150 × 1019/L [21]. Transaminase levels
and signs of allergic reactions were also recorded for every
study patient.
Statistical analysis
Pre- and postoperative anticoagulation therapy groups,
and subgroups among the recipients of preoperative
anticoagulation therapy, were compared using the Chi-
square tests and Non-parametric tests. Analyses were
performed using Statistical Product and Service Solu-
tions statistical software (Spss19.0). A value of P < 0.05
was considered statistically significant.
Results
Patient characteristics
A total of 222 patients (81 males, 141 females) met the
criteria for inclusion, of whom 111 were admitted with
femoral neck fractures and 111 with intertrochanteric
fractures. The mean age of patients was 75 ± 8 (S.D.)
years. Among study patients, 81, 30 and 111 underwent
total hip arthroplasty, hemi-arthroplasty, and fixation with
proximal femoral nail anti-rotation, respectively. 23 pa-
tients received combined spinal-epidural anesthesia, while
145 and 54, respectively, were subjected to spinal and gen-
eral anesthesia. Table 1 shows the group characteristics
among recipients of pre- and postoperative anticoagulation
therapy. Table 2 depicts patient characteristics in the sub-
groups with received initiation of anticoagulation therapy
1–3 days before surgery (group A), 4–6 days before surgery
(group B), 7–9 days before surgery (group C), and 10–12
days before surgery (group D).
Treatment data
The mean duration of surgery was 176 ± 34 min. Mean
blood loss was estimated to be 216 ± 135 mL, with 15
patients requiring intraoperative blood transfusion and
93 needing postoperative blood transfusion. Mean post-
surgical wound drainage, collected from tubes placed ac-
cording to surgical conventions, amounted to 225 ± 133
mL and mean time till drain removal was 2 days, while
mean length of hospital stay was 20 ± 4 days.
Incidence of complications
Among recipients of preoperative anticoagulation therapy,
two patients developed postoperative PE, of whom one
died and one was successfully treated by thrombolysis.
Only one patient developed DVT in the preoperative
group, and he was successfully treated with thrombolysis
and supportive measures. In the group receiving postoper-
ative initiation of anticoagulation therapy, one patient
each developed PE and DVT, both of whom recovered
with symptomatic treatment only. There was no difference
in the occurrence of PE and DVT between the two groups
(P>0.05, Chi-square tests).
In the preoperative group, five patients suffered from
minor wound bleeding, indicated by wound ecchymosis
and bleeding. In the same group, one patient developed
Table 1 Characteristics of patients who received preoperative and postoperative initiation of anticoagulation therapy
Characteristics Preoperative anticoagulation group Postoperative anticoagulation group Total P value
(n=133) (n=89) (n=222)
Basic Information
Age(years), mean ± SD 76±9 73±14 75±8 0.396
Gender
Male 52 29 81
Female 81 60 141
Body weight (kg), mean ± SD 58.87±11.34 58.76±10.57 58.83±11.01
Body mass index, mean ± SD 22.20±3.58 22.32±3.80 22.25±3.50 0.506
Comorbid conditions, n (%)
Hypertension 36 (27.06) 20 (22.47) 56 (25.23)
Diabetes 33 (24.81) 17 (19.10) 50 (22.53)
Congestive heart failure 5 (3.76) 1 (1.12) 6 (2.70)
Varicose veins 4 (3.01) 4 (4.49) 8 (3.60)
Currently active cancer 0 (0) 0 (0) 0 (0)
Paralysis of lower limbs 7 (5.26) 3 (3.37) 10 (4.5)
Atrial fibrillation 11 (8.27) 4 (4.49) 15 (6.76)
Prior stroke or TIA 7 (5.26) 5 (5.62) 12 (5.41)
Liu et al. BMC Musculoskeletal Disorders  (2016) 17:76 Page 4 of 8
a suspected allergic skin reaction, characterized by
rashes over abdomen and lower limbs, but no change in
heart rate or blood pressure. The condition was treated
successfully with medication. In the group receiving
postoperative anticoagulation therapy only, three pa-
tients developed minor wound bleeding, one suffered
from suspected heparin-induced thrombocytopenia (suc-
cessfully treated by platelet transfusion and symptomatic
treatment), and one had a mild increase in serum trans-
aminase levels. None of the study patients required dis-
continuation of LMWH therapy. Spinal anesthesia was
administered to 168 patients, with no cases of postoper-
ative intraspinal hematoma (Table 3, Table 4).
Discussion
Patients undergoing hip fracture surgery are at increased
risk of VTE, especially in those with additional risk fac-
tors. Without prophylaxis, rate of postoperative VTE can
be as high as 40–60 %, with no major differences in rates
between Asian and Western countries [1, 22]. Chemical
prophylaxis in these patients was considered appropriate.
In spite of that, bleeding complications was the major
concern of surgeons during chemoprophylaxis, and
should be considered when deciding on the time of initi-
ation of therapy [23, 24]. A literature review by Dahl et al.
[4] found that, among patients undergoing total hip
arthroplasty, the dose, administration time (preoperative
initiation of 40 mg daily vs. postoperative initiation of 30
mg twice daily) and duration of use of enoxaparin (5–14
days vs. 28–39 days) were not associated with major
bleeding events. In the present study, there was no
occurrence of major hemorrhagic complications, and only
eight cases of wound bruising or oozing, suggesting that
administration of LMWH is quite safe. Previous reports
have indicated that adverse reactions of LMWH are low,
and no serious adverse reactions were observed in this
study. One case had a mild elevated aminotransferase level
and one had a suspicious allergic reaction, but LMWH
was not discontinued in any of these cases. For the patient
with a suspicious allergic reaction, no further examina-
tions were taken since the skin rash disappeared after top-
ical drug treatment.
This study included patients at high risk of VTE, who
received regular LMWH administration along with ad-
junct mechanical therapy measures. Preoperative antic-
oagulation therapy was initiated 1–12 days prior to
surgery, as soon as the patient was admitted to hospital,
and postoperative anticoagulation therapy was initiated
12 h after completion of surgery. Drain removal was 3 h
prior to LMWH administration, thus reducing the risk
of bleeding during the removal process. DVT and PE
diagnosis during anticoagulation treatment were made
strictly in accordance with the patient's clinical mani-
festations and laboratory test results, with suspicious
cases undergoing lower limb compression color Doppler
ultrasonography or computed tomography pulmonary
angiography.
Both ACCP [“Prevention of Venous Thromboembolism
in Orthopedic Surgery Patients: Antithrombotic Therapy
and Prevention of Thrombosis” (9th edition, 2012)]
and AAOS guidelines [“Clinical Practice Guideline on
Preventing Venous Thromboembolic Disease in Patients
Table 2 Patients’ characteristics according to the time of initiation of preoperative anticoagulation therapy
Characteristics Group A Group B Group C Group D Total P value
(n=54) (n=57) (n=15) (n=7) (n=133)
Basic Information
Age (years),mean ± SD 76±11 75±8 76±8 79±4 76±9 0.647
Gender
Male 22 20 7 3 52
Female 32 37 8 4 81
Body weight (kg), mean ± SD 58.31±11.55 58.96±12.01 61±9.96 57.71±9.36 58.87±11.34
Body mass index, mean ± SD 22.08±3.94 22.28±3.68 22.46±2.71 22.08±3.94 21.83±58.10 0.971
Comorbid conditions, n (%)
Hypertension 11 (20.37) 13 (22.81) 8 (53.33) 4 (57.14) 36 (27.06)
Diabetes 9 (16.67) 14 (24.56) 7 (46.67) 5 (71.43) 33 (24.81)
Congestive heart failure 3 (5.56) 1 (1.75) 0 (0) 1 (14.29) 5 (3.76)
Varicose veins 2 (3.70) 1 (1.75) 1 (6.67) 0 (0) 4 (3.01)
Currently active cancer 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Paralysis of lower limbs 2 (3.70) 4 (7.02) 1 (6.67) 0 (0) 7 (5.26)
Atrial fibrillation 5 (9.26) 4 (7.02) 1 (6.67) 1 (14.29) 11 (8.27)
Prior stroke or TIA 2 (3.70) 4 (7.02) 1 (6.67) 0 (0) 7 (5.26)
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Undergoing Elective Hip and Knee Arthroplasty” (2011)]
recommend anticoagulation therapy for DVT prophylaxis
for patients undergoing hip or knee arthroplasty or surgi-
cal treatment of hip fractures [2, 17]. The ACCP and
AAOS guidelines also suggest LMWH as the preferred
agent for DVT prophylaxis [1]. It can be noted that
LMWH is the most commonly used drug for the preven-
tion of postoperative DVT in the United States [25]. The
most common time of initiation of anticoagulation
therapy was reported to be 13–24 h after surgery (35 %).
Mont M [26] highlighted that preoperative initiation of
anticoagulation therapy had been based on a theory that
ascribe surgical trauma as the principal cause of DVT, and
postoperative initiation of prophylaxis might be adequate
because DVT usually develops over a prolonged period of
time (several days to weeks). They further argued that
postoperative initiation of prophylaxis should be favored
as it reduced the risks associated with spinal anesthesia
and surgery.
Some researchers have recommended against pre-
operative initiation of anticoagulation therapy under the
assumption that it may increase the rate of postoperative
intraspinal hematoma in patients receiving spinal
anesthesia. Occurrence of spinal cord edema following
spinal anesthesia is quite rare (1:150 000), and the risk
of spinal hematoma in women undergoing knee
arthroplasty is only 1:3600 [23, 27]. Hull et al. performed
a meta-analysis of studies on effectiveness and safety of
preoperative and postoperative initiation of LMWH
therapy in elective hip joint replacement surgery pa-
tients. The study found that, among patients undergoing
preoperative and postoperative initiation of therapy, the
incidence of DVT were 10 % and 15.3 %, respectively (P
= 0.02), and, contrary to expectation, the incidence of
major bleeding events was lower in patients with pre-
operative rather than postoperative initiation of therapy
(0.9 % vs 3.5 %, P = 0.01) [24].
Our study did not detect any significant differences in
the effectiveness of DVT or PE prevention between initi-
ation of LMWH therapy ≥12 h before surgery and ≥12 h
after surgery. No cases of postoperative intraspinal
hematoma were detected among the 168 study patients
who received spinal anesthesia for total hip arthroplasty
or hip fracture fixation surgery. Preoperative initiation of
anticoagulation therapy did not increase the risk of
intraspinal hematoma. Moreover, no significant differ-
ences were detected in terms of intraoperative blood loss,
postoperative wound drainage, change in hemoglobin
concentration after surgery, and change in hematocrit
after surgery among subgroups of patients in whom antic-
oagulation therapy were initiated 1–3 days, 4–6 days, 7–9
days, and 10–12 days before surgery.
Table 3 Surgical and postoperative information, efficacy and safety in patients receiving preoperative and postoperative initiation of
anticoagulation therapy
Characteristics Preoperative Anticoagulation group Postoperative anticoagulation group Total P value
(n=133) (n=89) (n=222)
Surgical information
General anaesthesia, n (%) 37 (27.82) 17 (19.10) 54 (34.32)
Surgery time (min),mean ± SD 173±43 180±53 176±34 0.287
Intraoperative bleeding (mL),mean ± SD 208±183 228±179 216±135 0.204
Intraoperative blood transfusion, n (%) 9 (6.77) 6 (6.74) 15 (6.76)
Postoperative information
Postoperative blood transfusion, n (%) 22 (16.54) 13 (14.61) 35 (15.77)
Postoperative drainage (mL),mean ± SD 212±154 244±196 225±133 0.403
Reduction in hemoglobin concentrations (g/L) 23±11 27±13 25±14 0.143
Hospital stays(days),mean ± SD 20±5 19±6 20±4 0.104
Efficacy assessment, n (%)
Symptomatic DVT 1 (0.75) 1 (1.1) 2 (0.90)
Symptomatic PE 2 (1.5) 1 (1.1) 3 (1.35)
Safety assessment, n (%)
Major bleeding 0 (0) 0 (0) 0 (0)
Minor bleeding 5 (3.76) 3 (3.37) 8 (3.60)
Thrombocytopenia 0 (0) 1 (1.1) 1 (0.45)
Elevated aminotransferase 0 (0) 1 (1.1) 1 (0.45)
Suspicious allergic reaction 1 (0.75) 0 (0) 1 (0.45)
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Our study has several limitations. First, this is a single-
centered, retrospective observational study subject to in-
herent biases including unmeasured confounding, selec-
tion, and ascertainment bias. Second, the patients enrolled
in the study have different fracture types, femoral neck
fractures (Garden III-IV), intertrochanteric fractures (Ev-
ans-JensenI-V); it is possible that complex fractures may
affect the final result, associated with an increase in oper-
ation time and a higher postoperative morbidity. Third,
we identified potential DVT cases on the basis of clinical
features, e.g. lower extremity swelling, pain, stiffness,
superficial venous congestion, and increase in skin
temperature, without performing routine angiography or
color Doppler ultrasonography in all patients. This may
have resulted in failure to detect DVT cases with minimal
or no clinical signs [28], thereby reducing the validity of
outcome data. Fourth, the sample size of the groups and
subgroups is not great. Finally, post-discharge medical rec-
ord follow-up was imperfect, therefore, it is possible that
some venous thromboembolism events may have oc-
curred after hospital discharge and were missed.
Conclusions
Although early initiation of anticoagulation therapy is al-
ways regarded as more effective in reducing risk of VTE,
and postoperative initiation of anticoagulation therapy is
considered safer than preoperative initiation, the above re-
sults indicate that preoperative initiation of anticoagula-
tion therapy with LMWH may not increase intraoperative
or postoperative risk of bleeding, but also does not signifi-
cantly reduce the risk of postoperative DVT or PE, com-
pared to postoperative initiation. Our study may provide a
reference in choosing the appropriate methods to prevent
the perioperative venous thromboembolism, but further
studies with more accurate diagnostic methods may pave
the way for evidence-based intervention in this regard.
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Postoperative drainage (mL),mean ± SD 201±157 203±149 259±188 260±81 212±154 0.277
Reduction in hemoglobin concentrations (g/L) 24±11 24±10 18.±14 15±10 23±11 0.375
Hospital stays(days),mean ± SD 18±4 21±4 24±7 23±7 20±5 0.00
Efficacy assessment, n (%)
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Symptomatic PE 1 (1.85) 0 (0) 1 (6.67) 0 (0) 2 (1.50)
Safety assessment, n (%)
Major bleeding 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Minor bleeding 1 (1.85) 0 (0) 2 (13.3) 2 (28.6) 5 (3.76)
Thrombocytopenia 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
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